U.S. Jury Rules Against Takeda Pharmaceutical Company in Generic Drug Delay Case
A U.S. federal jury ruled that Takeda Pharmaceutical (TAK) violated antitrust laws by delaying the introduction of a generic version of Amitiza through an alleged 'pay-for-delay' agreement, ordering substantial damages. The ruling could pose significant legal and financial risks for the company.
Tickers: $TAK
Topics: Litigation Pharmaceuticals Regulatory Risk